Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment

References

• Feldmann M., Maini R. N. Anti‐TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001; 19: 163–96
   PubMed Web of Science ®Google Scholar
• Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9
   PubMed Web of Science ®Google Scholar
• Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602
   PubMed Web of Science ®Google Scholar
• Braun J., Baraliakos X., Brandt J., Sieper J. Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides. Scand J Rheumatol 2005; 34: 178–90
   PubMed Web of Science ®Google Scholar
• van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo‐controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582–91
   PubMed Web of Science ®Google Scholar
• Flendrie M., Creemers M. C., Welsing P. M., den Broeder A. A., van Riel P. L. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl 2): ii30–3
   PubMedGoogle Scholar
• Wendling D., Materne G. E., Michel F., Lohse A., Lehuede G., Toussirot E., et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 2005; 72: 309–12
   PubMedGoogle Scholar
• Voulgari P. V., Alamanos Y., Nikas S. N., Bougias D. V., Temekonidis T. I., Drosos A. A. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005; 118: 515–20
   PubMed Web of Science ®Google Scholar
• Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova‐Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403–12
   PubMed Web of Science ®Google Scholar
• Dixon W. G., Watson K., Lunt M., Hyrich K. L., Silman A. J., Symmons D. P., et al. Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti‐tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368–76
   PubMed Web of Science ®Google Scholar
• Salliot C., Gossec L., Ruyssen‐Witrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumour necrosis factor‐{alpha} blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2006
   Google Scholar
• Wasserman M. J., Weber D. A., Guthrie J. A., Bykerk V. P., Lee P., Keystone E. C. Infusion‐related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004; 31: 1912–17
   PubMed Web of Science ®Google Scholar
• [Working group set by Finnish Medical Society Duodecim and Finnish Society for Rheumatology, Helsinki, Finland., Rheumatoid arthritis Current Care Guideline (update June 2003). Finland Medical Society Duodecim], in Finnish (www.kaypahoito.fi)
   Google Scholar
• Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35
   PubMed Web of Science ®Google Scholar
• Mottonen T., Hannonen P., Leirisalo‐Repo M., Nissila M., Kautiainen H., Korpela M., et al. Comparison of combination therapy with single‐drug therapy in early rheumatoid arthritis: a randomised trial. FIN‐RACo trial group. Lancet 1999; 353: 1568–73
   PubMed Web of Science ®Google Scholar
• Carmona L., Gomez‐Reino J. J., BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72
   PubMed Web of Science ®Google Scholar
• Nordstrom D. C., Konttinen L., Korpela M., Tiippana‐Kinnunen T., Eklund K., Forsberg S., et al. Classic disease modifying anti‐rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int 2005; 1–8
   Google Scholar
• Mutru O., Laakso M., Isomaki H., Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985; 290: 1797–9
   PubMed Web of Science ®Google Scholar
• Doran M. F., Crowson C. S., Pond G. R., O'Fallon W. M., Gabriel S. E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294–300
   PubMed Web of Science ®Google Scholar
• Capell H. A. Disease modifying antirheumatic drugs: long‐term safety issues. J Rheumatol Suppl 2001; 62: 10–15
   PubMedGoogle Scholar
• Doran M. F., Crowson C. S., Pond G. R., O'Fallon W. M., Gabriel S. E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population‐based study. Arthritis Rheum 2002; 46: 2287–93
   PubMed Web of Science ®Google Scholar
• Keane J., Gershon S., Wise R. P., Mirabile‐Levens E., Kasznica J., Schwieterman W. D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha‐neutralizing agent. N Engl J Med 2001; 345: 1098–104
   PubMed Web of Science ®Google Scholar
• Gomez‐Reino J. J., Carmona L., Valverde V. R., Mola E. M., Montero M. D., BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active‐surveillance report. Arthritis Rheum 2003; 48: 2122–7
   PubMed Web of Science ®Google Scholar
• World Health Organization, Tuberculosis country profile/Finland (www.who.int/globalatlas/dataQuery/default.asp)
   Google Scholar
• World Health Organization, Tuberculosis: infection and transmission (www.who.int/mediacentre/factsheets/fs104/en/index.html#global)
   Google Scholar
• Konttinen L., Honkanen V., Uotila T., Pollanen J., Waahtera M., Romu M., et al. Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 2006; 26: 916–22
   PubMed Web of Science ®Google Scholar
• Vidal F., Fontova R., Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003; 139: W–63
   PubMedGoogle Scholar
• Favalli E. G., Varenna M., Sinigaglia L. Drug‐induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 2005; 23: 247–50
   PubMed Web of Science ®Google Scholar
• Montane E., Salles M., Barriocanal A., Riera E., Costa J., Tena X. Antitumor necrosis factor‐induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol 2007; 26: 1527–9
   PubMed Web of Science ®Google Scholar
• Germano V., Picchianti Diamanti A., Baccano G., Natale E., Onetti Muda A., et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519–20
   PubMed Web of Science ®Google Scholar
• Bongartz T., Sutton A. J., Sweeting M. J., Buchan I., Matteson E. L., Montori V. Anti‐TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta‐analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006; 295: 2275–85
   PubMed Web of Science ®Google Scholar
• Hyrich K. L., Silman A. J., Watson K. D., Symmons D. P. Anti‐tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004; 63: 1538–43
   PubMed Web of Science ®Google Scholar